NASDAQ:CYAD
Delisted

Celyad Sa Stock Signals

etoro logo Buy CYAD
*Your capital is at risk
$0.470
+0 (+0%)
At Close: Aug 17, 2023

Latest Data & Signals Issued

Below are some of the latest signals issued for Celyad SA

General

Signal Type Signal Value Data
Score 0.000 61 days ( 0 %
Last Price $0.470 0 %
Performance History
7 Days
$0.470 $0.470
0%
30 Days
$0.470 $0.470
0%
12 Mos
$2.08 $0.470
-77.40%

5/18

Active Buy Signals

Specific Signals

Short Term
Net score: 30.41
Signal Type Signal Value Importance Data
High / Low N/A Very Low $0.470 - $0.470
Trend - 3 mos 0 % High Width: 0.00000000000017 %
Pred. range - 3 mos $0.470 - $0.470 Low 0 % - 0 %
Volume Direction Sell High Volume: 1 · Direction: 0
Pivot Short Buy Very Low Aug 16, 2023 - 2 days
RSI Short Pivot Signal Buy Very Low Jun 01, 2023 - 54 days
Short MA 3 mos Sell Low Nov 30, -0001 - N/A days
Long MA 3 mos Sell Medium Nov 30, -0001 - N/A days
Short/Long MA 3 mos Sell Medium Nov 30, -0001 - N/A days

Unlock Short Term Signals

Get access to powerful short-term trading signals and real-time market insights

Subscribe Now
Long Term
Net score: 22.83
Signal Type Signal Value Importance Data
Trend - 12 mos -43.79 % Very High Width: 397.63 %
Pred. range - 12 mos N/A - $0.92 High -100.00 % - 94.83 %
Short MA 12 mos Sell Very High Apr 12, 2023 - 89 days
Long MA 12 mos Sell Very High Mar 01, 2023 - 118 days
Short/Long MA 12 mos Sell Very High Mar 14, 2023 - 109 days
Pivot Long Buy Low May 18, 2023 - 63 days
RSI Long Pivot Signal Buy Low Jun 12, 2023 - 47 days
Bollinger Sell Medium Nov 30, -0001 - N/A days
MACD Neutral High No Dates Stored For This Signal
Click to get the best stock tips daily for free!
ABOUT CELYAD SA
Celyad SA
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE